|Marvin L. White|
President and CEO
Mr. White leads Aptevo Therapeutics as the President and CEO. Prior to this role, he was a member of Emergent BioSolutions’ Board of Directors. He is the former Chief Financial Officer of St. Vincent’s Health, a $2.8 billion multi-hospital health system. Mr. White previously served as Executive Director and CFO of Lilly USA, a subsidiary of Eli Lilly and Company, and held other positions in corporate finance at Eli Lilly and Company. He serves on the boards of CoLucid Pharmaceuticals, Inc., WP Glimcher, and OneAmerica Financial Partners Inc.
SVP and Chief Financial Officer
Mr. Lamothe leads Finance, Business Development, Investor Relations, and IT. Prior to Aptevo Therapeutics, he was Emergent’s VP Finance, Biosciences Division. Mr. Lamothe assumed this role in 2014 when Emergent concluded the acquisition of Cangene Corporation, where he was Chief Financial Officer. Mr. Lamothe’s business experience is built on a 25+ year career, spanning several industries and both CFO and CEO roles. Prior to Cangene Corporation, Mr. Lamothe was the Chief Financial Officer for Smith Carter Architects and Engineers Incorporated. He also previously served as President and Chief Executive Officer of Kitchen Craft Cabinetry after occupying the position of VP Finance and Chief Financial Officer with that organization. Mr. Lamothe’s other past experience includes serving as Chief Financial Officer for Motor Coach Industries and he has held various roles at James Richardson & Sons, Limited and Ernst & Young LLP.
|Scott C. Stromatt, M.D.|
Chief Medical Officer and SVP, Clinical Development & Medical Affairs
Dr. Stromatt is the Chief Medical Officer at Aptevo Therapeutics, a position he held for the last eight years at Emergent. He leads Clinical Research, Medical Affairs, Pharmacovigilance, and Regulatory Affairs, and the clinical development programs for the ADAPTIR molecules that he designed. Dr. Stromatt has nearly three decades of experience at biotechnology and pharmaceutical companies, including being a biotechnology analyst for Wall Street investment firm C.E. Unterberg. Dr. Stromatt has conducted over 55 clinical trials in a wide variety of indications, including oncology, rheumatology, pulmonology, gastroenterology, and neurology.
|Randy J. Maddux|
Mr. Maddux leads the Quality, Process and Analytical Development, Engineering and Facilities, and Supply Chain functions for the company. Prior to joining Aptevo Therapeutics, he spent 4 years as a VP and Site Director at GSK, where he led the largest biopharmaceutical development and manufacturing site within the GSK manufacturing network. Prior to GSK, Mr. Maddux spent 9 years at Human Genomes Sciences as VP Quality and Operations and 8 years with Biogen in positions of increasing responsibility within the Quality organization. During his 20+ years in biotech, he served in key roles supporting the licensure and launch of several successful products including Avonex, Tysabri, Benlysta, and Raxibacumab. Mr. Maddux serves on the Life Sciences Foundation Board at Montgomery College.
|Jane Gross, Ph.D.|
VP, Research & Non-Clinical Development
Dr. Gross leads research and non-clinical development focusing on the development of novel protein therapeutics based on the ADAPTIRTM platform, a position she has held for the last five years at Emergent. She leads research efforts in molecular biology and protein engineering, immunology, protein and cell sciences, and translational research for clinical development. Dr. Gross has a Ph.D. in Immunology and over twenty-five years of experience in the discovery and development of novel protein therapeutics in autoimmune, infectious disease and oncology indications and is an inventor on over 100 patents. Prior to joining Emergent, Dr. Gross served as VP of Immunology Research at ZymoGenetics Inc., where she led efforts in discovery and development of therapeutics from novel genes for treatment of AIID and cancer.
VP, Commercial Operations
Mr. Adelman leads all commercial functions at Aptevo Therapeutics as VP, Commercial Operations, a position that he has held since 2012 at Cangene Corporation, which was acquired by Emergent in 2014. Mr. Adelman brings over 20 years of industry-specific commercial leadership experience in areas including sales, marketing, contracting, pricing, commercial analytics, and alliance management. Prior to joining Cangene, Mr. Adelman was VP of Marketing and Sales at Adolor Corporation and Sr. Director, Marketing Strategy at AstraZeneca.
VP and General Counsel
Ms. Mitchell leads Governance, SEC, Intellectual Property, Contracts, and Compliance. Her previous role was VP, Associate General Counsel and Assistant Secretary of Emergent, where she provided strategic legal advice in a variety of areas, including corporate governance, healthcare regulatory, and product development, and served as lead negotiator on various transactions. Prior to Emergent, Ms. Mitchell was an Associate at Ropes & Gray LLP, where she advised health care, life sciences, and technology clients in mergers and acquisitions, venture capital investment, and debt transactions.